Production Method 1

105-36-2

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Acetone ;  overnight, reflux

Reference

5-Bromo-norborn-2-en-7-one derivatives as a carbon monoxide source for palladium catalyzed carbonylation reactions

Payne, China M.; Cho, Kyulee; Larsen, David S., RSC Advances, 2019, 9(53), 30736-30740

Production Method 2

105-39-5

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  16 h, rt

Reference

Vinylboronic Acids as Efficient Bioorthogonal Reactants for Tetrazine Labeling in Living Cells

Eising, Selma; van der Linden, Nicole G. A.; Kleinpenning, Fleur; Bonger, Kimberly M., Bioconjugate Chemistry, 2018, 29(4), 982-986

Production Method 3

105-39-5

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  16 h, rt

Reference

Modular, Bioorthogonal Strategy for the Controlled Loading of Cargo into a Protein Nanocage

Schoonen, Lise; Eising, Selma; van Eldijk, Mark B.; Bresseleers, Jaleesa; van der Pijl, Margo; et al, Bioconjugate Chemistry, 2018, 29(4), 1186-1193

Production Method 4

105-39-5

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  overnight, rt
1.2 Reagents: Water

Reference

Synthesis and biological evaluation of ortho-carborane containing benzoxazole as an inhibitor of hypoxia inducible factor (HIF)-1 transcriptional activity

Nakamura, Hiroyuki; Yasui, Yuka; Ban, Hyun Seung, Journal of Organometallic Chemistry, 2013, 747, 189-194

Production Method 5

105-39-5

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  overnight, rt
1.2 Reagents: Water ;  rt

Reference

Discovery of Carboranes as Inducers of 20S Proteasome Activity

Ban, Hyun Seung; Minegishi, Hidemitsu; Shimizu, Kazuki; Maruyama, Minako; Yasui, Yuka; et al, ChemMedChem, 2010, 5(8), 1236-1241

Production Method 6

105-39-5

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  rt

Reference

Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1α inhibitors

Shimizu, Kazuki; Maruyama, Minako; Yasui, Yuka; Minegishi, Hidemitsu; Ban, Hyun Seung; et al, Bioorganic & Medicinal Chemistry Letters, 2010, 20(4), 1453-1456

Production Method 7

609-15-4

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Dimethylformamide ;  overnight, rt

Reference

Catalyst as colour indicator for endpoint detection to enable selective alkyne trans-hydrogenation with ethanol

Wang, Yulei ; Huang, Zhidao ; Huang, Zheng, Nature Catalysis, 2019, 2(6), 529-536

Production Method 8

105-36-2

90794-33-5

Reaction Conditions

1.1 Reagents: Sodium hydride Solvents: Tetrahydrofuran ;  30 min, rt
1.2 rt; 1.5 h, rt

Reference

Synthesis of Biphenyl Proteomimetics as Estrogen Receptor-α Coactivator Binding Inhibitors

Williams, Anna B.; Weiser, Patrick T.; Hanson, Robert N.; Gunther, Jillian R.; Katzenellenbogen, John A., Organic Letters, 2009, 11(23), 5370-5373

Production Method 9

105-36-2

90794-33-5

Reaction Conditions

1.1 Reagents: Potassium carbonate Solvents: Acetone ;  12 - 96 h, rt

Reference

Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes

Christiansen, Elisabeth; Urban, Christian; Merten, Nicole; Liebscher, Kathrin; Karlsen, Kasper K.; et al, Journal of Medicinal Chemistry, 2008, 51(22), 7061-7064

ethyl 2-(4-iodophenoxy)acetate Raw materials

• ethyl 2-chloroacetate
• Ethyl bromoacetate
• Ethyl 2-chloroacetoacetate

ethyl 2-(4-iodophenoxy)acetate Preparation Products

• ethyl 2-(4-iodophenoxy)acetate (90794-33-5)

• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenoxyacetic acid derivatives

Ethyl 2-(4-Iodophenoxy)acetate (CAS No. 90794-33-5): An Overview of Its Synthesis, Applications, and Recent Research

Ethyl 2-(4-iodophenoxy)acetate (CAS No. 90794-33-5) is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique molecular structure, plays a crucial role in the synthesis of various bioactive molecules and serves as an important intermediate in the development of novel therapeutic agents.

The molecular formula of ethyl 2-(4-iodophenoxy)acetate is C₁₀H₁₁I O₃, and it has a molecular weight of approximately 288.1 g/mol. The compound features an iodine atom attached to a phenyl ring, which is further linked to an acetate ester group. This structural arrangement imparts unique chemical properties that make it valuable in various synthetic pathways.

In recent years, ethyl 2-(4-iodophenoxy)acetate has been extensively studied for its potential applications in the synthesis of bioactive compounds. One notable area of research involves its use as a building block in the development of antitumor agents. Studies have shown that derivatives of this compound exhibit significant antiproliferative activity against various cancer cell lines, making it a promising candidate for further investigation in oncology.

Another important application of ethyl 2-(4-iodophenoxy)acetate is in the field of drug delivery systems. Researchers have explored its use as a prodrug precursor, where the ester group can be hydrolyzed under physiological conditions to release the active moiety. This approach enhances the solubility and bioavailability of the drug, thereby improving its therapeutic efficacy.

The synthesis of ethyl 2-(4-iodophenoxy)acetate typically involves several steps, starting with the reaction of 4-iodophenol with ethyl bromoacetate in the presence of a base such as potassium carbonate. The resulting intermediate is then purified and characterized using techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). These analytical methods provide detailed insights into the structure and purity of the compound, ensuring its suitability for further applications.

Recent advancements in synthetic methodologies have led to more efficient and environmentally friendly routes for the production of ethyl 2-(4-iodophenoxy)acetate. For instance, green chemistry approaches have been developed to minimize waste generation and reduce the use of hazardous reagents. These methods not only enhance the sustainability of the synthesis process but also align with global efforts to promote greener chemical practices.

In addition to its synthetic utility, ethyl 2-(4-iodophenoxy)acetate has been investigated for its potential biological activities. Studies have demonstrated that this compound exhibits moderate antioxidant properties, which could be beneficial in preventing oxidative stress-related diseases. Furthermore, preliminary research suggests that it may have anti-inflammatory effects, making it a potential lead compound for developing new anti-inflammatory drugs.

The pharmaceutical industry's interest in ethyl 2-(4-iodophenoxy)acetate is driven by its potential to address unmet medical needs. For example, its use in the synthesis of targeted therapies for specific cancer types could revolutionize cancer treatment strategies. Additionally, its role as a prodrug precursor offers new opportunities for improving drug delivery and enhancing patient outcomes.

Despite its promising applications, further research is needed to fully understand the pharmacological properties and safety profile of ethyl 2-(4-iodophenoxy)acetate. Clinical trials are currently underway to evaluate its efficacy and safety in human subjects. These trials will provide valuable data that can guide future drug development efforts and ensure that this compound reaches its full therapeutic potential.

In conclusion, ethyl 2-(4-iodophenoxy)acetate (CAS No. 90794-33-5) is a multifaceted compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure and versatile synthetic applications make it an important molecule for scientists and researchers working on novel therapeutic agents. As ongoing studies continue to uncover new insights into its properties and applications, ethyl 2-(4-iodophenoxy)acetate is poised to play a crucial role in advancing medical science and improving patient care.

• 1984-60-7(Acetic acid,2-phenoxy-, 2-hydroxyethyl ester)
• 60359-62-8(Acetic acid, methoxy-, 2-phenoxyethyl ester)
• 1878-94-0(2-(4-Iodophenoxy)acetic Acid)
• 2555-49-9(Ethyl phenoxyacetate)
• 14316-61-1(Phenoxyacetic anhydride)
• 18598-23-7(Acetic acid,2-(4-methoxyphenoxy)-, ethyl ester)
• 81720-18-5(Methyl 2-(4-Iodophenoxy)acetate)
• 90347-82-3(Acetic acid, (2,4,6-triiodophenoxy)-, methyl ester)
• 90888-04-3(Ethyl (3-Iodophenoxy)acetate)
• 60359-58-2(Acetic acid, (acetyloxy)-, 2-phenoxyethyl ester)